{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:28:12Z","timestamp":1791203292119,"version":"4.2.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Obsessive-compulsive disorder (OCD) ranks as the fourth most prevalent psychiatric disorder, with selective serotonin reuptake inhibitors (SSRIs) as its mainstay pharmacological treatment. However, approximately 40 to 60% of patients do not adequately respond to initial treatment, highlighting the need for alternative options. N-acetylcysteine (NAC) is one of the several medications that have been used in augmentation with SSRIs to enhance their efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to investigate the safety and efficacy of NAC, a glutamate-modulating agent, as an augmentation in the treatment of moderate to severe OCD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We conducted a thorough search across PubMed, Scopus, Web of science, and ProQuest to identify relevant trials published until December 2023. The primary outcome of interest was the mean difference between the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores before and after administrating augmented NAC among patients with moderate to severe OCD. Furthermore, we compared the occurrence of adverse drug events between the experimental and control groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included six randomized controlled trials with 195 patients. The results of our study indicated a positive outcome for the experimental group in terms of the total Y-BOCS score when using the medication for a period of five to eight weeks (p-Value = 0.05). However, no significant difference was observed for durations shorter than five weeks or longer than 12 weeks. Additionally, no significant difference was found between the two groups in terms of the obsession and compulsion Y-BOCS scores. Furthermore, no significant differences were observed in terms of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Augmentation of NAC with SSRIs may benefit patients with moderate to severe OCD. However, it is necessary to conduct additional multi-center trials over extended periods to develop a comprehensive strategy for action.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42023463683.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2024.1421150","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T10:22:35Z","timestamp":1727086955000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Shayan","family":"Eghdami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Eissazade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Heidari Mokarar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Boroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Orsolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Shalbafan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"g2183","DOI":"10.1136\/bmj.g2183","article-title":"Obsessive-compulsive disorder","volume":"348","author":"Veale","year":"2014","journal-title":"Bmj"},{"key":"B2","volume-title":"Obsessive-compulsive disorder\u2013shifting paradigms","author":"Chitkara","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/biom13081220","article-title":"The neurobiological underpinnings of obsessive-compulsive symptoms in psychosis, translational issues for treatment-resistant schizophrenia","volume":"13","author":"Vellucci","year":"2023","journal-title":"Biomolecules"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.4103\/0019-5545.196976","article-title":"Clinical practice guidelines for Obsessive-Compulsive Disorder","volume":"59","author":"Janardhan Reddy","year":"2017","journal-title":"Indian J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2014.05.006","article-title":"Pharmacological treatment of obsessive-compulsive disorder","volume":"37","author":"Pittenger","year":"2014","journal-title":"Psychiatr Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1065812","article-title":"Therapies for obsessive-compulsive disorder: Current state of the art and perspectives for approaching treatment-resistant patients","volume":"14","author":"Swierkosz-Lenart","year":"2023","journal-title":"Front Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.32598\/bcn.2022.1604.3","article-title":"Cognitive rehabilitation for adult patients with obsessive-compulsive disorder: A systematic review of randomized controlled trials","volume":"15","author":"Bakizadeh","year":"2024","journal-title":"BCN"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119878177","article-title":"Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial","volume":"33","author":"Shalbafan","year":"2019","journal-title":"J Psychopharmacology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12888-021-03642-z","article-title":"Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial","volume":"22","author":"Askari","year":"2022","journal-title":"BMC Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"20837","DOI":"10.1038\/s41598-023-47931-x","article-title":"Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive\u2013compulsive disorder: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Eissazade","year":"2023","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.conb.2011.04.010","article-title":"Neurobiology of obsessive\u2013compulsive disorder: insights into neural circuitry dysfunction through mouse genetics","volume":"21","author":"Ting","year":"2011","journal-title":"Curr Opin neurobiology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-021-00534-6","article-title":"Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis","volume":"22","author":"Hadi","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S211703","article-title":"Investigating the role of glutamate in obsessive-compulsive disorder: current perspectives","volume":"16","author":"Karthik","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01841.x","article-title":"Ketosis and brain handling of glutamate, glutamine, and GABA","volume":"49","author":"Yudkoff","year":"2008","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1503\/jpn","article-title":"N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J Psychiatry Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/10715762.2018.1468564","article-title":"N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why","volume":"52","author":"Aldini","year":"2018","journal-title":"Free Radical Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/ijms23031268","article-title":"N-acetyl-aspartyl-glutamate in brain health and disease","volume":"23","author":"Morland","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2020.100529","article-title":"Efficacy and safety of N-acetylcysteine as add-on therapy in the treatment of obsessive-compulsive disorder: A systematic review and meta-analysis","volume":"25","author":"Gadallah","year":"2020","journal-title":"J Obsessive-Compulsive Related Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"W","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Internal Med"},{"key":"B20","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)","author":"Higgins","year":"2023"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The yale-brown obsessive compulsive scale: II. Validity","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res methodology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivy163","article-title":"Statistical Primer: heterogeneity, random- or fixed-effects model analyses","volume":"27","author":"Barili","year":"2018","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"B25","volume-title":"Evidence synthesis and meta-analysis for drug safety: report of CIOMS working group X","year":"2016"},{"key":"B26","doi-asserted-by":"publisher","first-page":"110550","DOI":"10.1016\/j.pnpbp.2022.110550","article-title":"N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial","volume":"117","author":"Sarris","year":"2022","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B27","article-title":"Efficacy of N-acetylcysteine augmentation on obsessive compulsive disorder: A multicenter randomized double blind placebo controlled clinical trial","volume":"12","author":"Ghanizadeh","year":"2017","journal-title":"Iran J Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomised, placebo-controlled study","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1177\/2167702616639864","article-title":"Participant characteristics as modifiers of response to N-acetyl cysteine (NAC) in obsessive-compulsive disorder","volume":"4","author":"Sarris","year":"2016","journal-title":"Clin psychol Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.9758\/cpn.2015.13.1.12","article-title":"N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review","volume":"13","author":"Oliver","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"686","DOI":"10.21203\/rs.3.rs-2684405\/v1","article-title":"Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial","volume":"23","author":"Shokrani","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archpsyc.1992.01820010029004","article-title":"Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder","volume":"49","author":"Swedo","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(91)90116-7","article-title":"Brain MRI in obsessive-compulsive disorder","volume":"36","author":"Kellner","year":"1991","journal-title":"Psychiatry Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12362","article-title":"Evaluation of oxidative metabolism and oxidative DNA damage in patients with obsessive\u2013compulsive disorder","volume":"70","author":"Alici","year":"2016","journal-title":"Psychiatry Clin neurosciences"},{"key":"B38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/brainsci12030342","article-title":"Smo-Shh agonist Purmorphamine prevents neurobehavioral and neurochemical defects in 8-OH-DPAT-induced experimental model of obsessive-compulsive disorder","volume":"12","author":"Gupta","year":"2022","journal-title":"Brain Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.49.6.540","article-title":"Obsessive-compulsive disorder with mitochondrial disease","volume":"49","author":"Lacey","year":"2008","journal-title":"Psychosomatics"},{"key":"B40","article-title":"The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence","volume":"65","author":"Denys","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90080-Y","article-title":"Cystine\/glutamate antiporter expression in retinal mu\u00a8 ller glial cells: Implications fordl-alpha-aminoadipate toxicity","volume":"57","author":"Kato","year":"1993","journal-title":"Neuroscience"},{"key":"B42","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.4103\/psychiatry.IndianJPsychiatry_517_18","article-title":"Neurocognitive deficits in obsessive\u2013compulsive disorder: A selective review","volume":"61","author":"Suhas","year":"2019","journal-title":"Indian J Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1421150\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T10:22:40Z","timestamp":1727086960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1421150\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":42,"alternative-id":["10.3389\/fpsyt.2024.1421150"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1421150","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1421150"}}